All the Active Ingredient Drugs
Aromatase Inhibitor. Letrozole 2.5 mg. F.C. TABS.: 30. 2.5 mg once daily.
Adjuv. tmt. of postmenop. women with
hormone recept. positive early breast
canc. Extend. adjuv. tmt. of early breast
canc. in postmenop. women who have
received prior standard adjuv. tamoxifen
ther. 1st -line tmt. in postmenop. women
with hormone recept. positive, or in
whom the hormone recept. status cannot
be determined, local. advanced or
metast. breast canc. Tmt. of advanced
breast canc.in post menop. women with
dis. progress. follow. anti-oestrogen ther.
C/I: Hypersens. Premenop. endocrine
status. Preg. Lact.
Aromatase Inhibitor. Letrozole 2.5 mg. F.C. TABS:30. 1 tab. dly.
Adjuv., extend. adjuv. setting, tmt to
cont. for 5 years/until tumor relapse occurs, whichever comes first.
Metastat. dis: Tmt. Until tumor
progress evident.
Child. and adolescents (under the age
of 18 years): not for use. No dose
adjust. Reqd. in elderly/ren. impar.
(CrCl>= 10ml/min)/hepat. Impair.
Severe hepat. Impair.(Child-Pugh score
C): keep under close supervision. See
lit.
First-line treatment in postmenopausal
women with hormone receptor positive or
in whome hormone receptor status
cannot be determined locally advanced or
metastatic breast cancer. Treatment of
advanced breast cancer in
postmenopausal women with disease
progression following antiestrogen
therapy. Extended adjuvant treatment of
early breast cancer in postmenopausal
women who have received prior standard
adjuvant tamoxifen therapy. Adjuvant
treatment of postmenopausal women
with hormone receptor positive early
breast cancer. See lit.
C/I: Pregnancy; breastfeeding;
Hypersensitivity to Letrozole or any of
the excipients; Premenopausal
endocrine status. See lit.
Aromatase Inhibitor. Letrozole 2.5 mg. F.C. TABS: 30. 1 tab dly. See lit.
Adjuv. tmt. early breast cancer in
postmenopaus. women. Tmt. adv. breast
cancer in women with natural/artific.
induced postmenopaus. status, also in pts
with dis. progr. while under tmt. with anti
estrogens. First line tmt. in postmenopaus.
women with progress./metast. breast
cancer. Extend. adjuv. tmt. of early breast
cancer in women with natural/artific.
induced postmenopaus. status follow.
stand. adjuv. tamoxifen ther.
C/I: Hypersens., pregn., lact.,
premenopaus. status, severe hepat. dis.
Aromatase Inhibitor. Letrozole 2.5 mg. TABS: 30. Adults, elderly: 1 tab 1 x dly
in adjuv./extend. adjuv. setting, tmt.
contin. 5 yrs/until tumor relapse. Pts.
metastat. dis., contin. tmt. until tumor
progress. evident. Child: Not for use.
Hepat./ren. impair: No dos. adjust
reqd.
First-line tmt. postmenopaus. women
with hormone recept. +ive or hormone recept. status cannot be determin., locally
advanced/ metastat. breast cancer. Tmt.
advanced breast cancer postmenopaus.
women with dis. progress. follow.
antiestrogen ther. Extend. adjuv. tmt.
early breast cancer in postmenopaus.
women who have received prior standard
adjuv. tamoxifen ther. Adjuv. tmt.
postmenopaus. women with hormone
receptor +ive early breast cancer.
C/I: Known hypersens., premenopaus.
endocrine status, pregn., lact., severe
hepat. dis.
